Summary: The University of Maryland have approved the first drug designed to treat patients with Duchenne muscular dystrophy.
Source: University of Maryland.
Researchers from the University of Maryland Fischell Department of Bioengineering’s (BIOE) Jewell Lab (link is external) reported today a new way to “turn off” the harmful immune attack that occurs during autoimmune diseases such as multiple sclerosis (MS), while keeping healthy functions of the immune system intact.
“Our lab is combining immunology and nanotechnology to reprogram how the immune system responds to self-cells in the brain that are mistakenly attacked during MS,” said BIOE Assistant Professor Christopher Jewell, corresponding author on the new report. “The finding, conducted in cells and pre-clinical animal models of MS, could lead to new approaches for reversing paralysis in MS, or better therapies for other autoimmune diseases.”
The group’s findings were published today in the journal Cell Reports. Collaborator Dr. Jonathan Bromberg from the University of Maryland School of Medicine said, “The studies show it is possible to treat and cure inflammatory disease with a single dose of therapeutics loaded in biodegradable polymers targeted directly to lymph nodes – the tissues that coordinate immune function in the body.”
In MS, the immune system incorrectly recognizes myelin that insulates and protects nerves fibers in the brain. Immune cells enter the brain and attack, leading to slow loss of motor function and other complications. Current therapies for MS work by decreasing the activity of the immune system; but, they do so in a broadly-suppressive way that often leaves patients vulnerable to infection. There are also no cures for MS, type 1 diabetes, and other autoimmune diseases.
“The goal of our work – and that of others in the field – is to expand cells that are both myelin-specific and regulatory in nature,” said Lisa Tostanoski, first author on the paper. “The hope is that these cells can directly suppress inflammation without targeting healthy immune function.”
Jewell’s team is working to reprogram the function of lymph nodes: instead of generating inflammatory cells that attack myelin, the lymph nodes are “instructed” to promote regulatory immune cells that control the attack against myelin. To carry out the “reprogramming,” degradable polymer particles that incorporate regulatory signals are delivered to lymph nodes using a unique intra-lymph node injection technique. Once in the lymph nodes, these particles slowly release immune signals to promote regulatory immune cells that mature and migrate to the central nervous system to suppress the attack against myelin.
In order to test their strategy, the team is using two rodent models of MS. The results are promising thus far, demonstrating that a single particle treatment can permanently reverse paralysis. Importantly, these effects were found to be myelin-specific, and correlated with local changes in the function and types of cells in lymph nodes and the central nervous system.
“Moving forward, our team is working to show the therapeutic effects result from repair and remyelination in the brain,” Jewell said. “That represents a goal that is a critical criterion to improve on human MS therapies.”
To support this breakthrough research, the National Multiple Sclerosis Society has awarded the team more than $600,000 in research funding.
“This innovative research has the potential to open up a new, highly selective approach to treating multiple sclerosis,” said Bruce F. Bebo, Ph.D., Executive Vice President of Research at the National Multiple Sclerosis Society. “We are pleased to have helped launch this work with early pilot and full research grants, and hope that the further research required to translate these results to people is equally successful.”
The additional authors on the work are BIOE researchers Dr. Yu-Chieh Chiu, Joshua Gammon, and James Andorko, and Dr. Thomas Simon at the University of Maryland School of Medicine.
Source: University of Maryland
Image Source: NeuroscienceNews.com image is credited to Kelly Finan.
Original Research: Full open access research for “Reprogramming the Local Lymph Node Microenvironment Promotes Tolerance that Is Systemic and Antigen Specific” by Lisa H. Tostanoski, Yu-Chieh Chiu, Joshua M. Gammon, Thomas Simon, James I. Andorko, Jonathan S. Bromberg, and Christopher M. Jewell in Cell Reports. Published online August 10 2016 doi:10.1016/j.celrep.2016.08.033
[cbtabs][cbtab title=”MLA”]University of Maryland “Reprogramming Lymph Nodes to Fight Multiple Sclerosis.” NeuroscienceNews. NeuroscienceNews, 19 September 2016.
<https://neurosciencenews.com/multiple-sclerosis-lymph-nodes-5077/>.[/cbtab][cbtab title=”APA”]University of Maryland (2016, September 19). Reprogramming Lymph Nodes to Fight Multiple Sclerosis. NeuroscienceNew. Retrieved September 19, 2016 from https://neurosciencenews.com/multiple-sclerosis-lymph-nodes-5077/[/cbtab][cbtab title=”Chicago”]University of Maryland “Reprogramming Lymph Nodes to Fight Multiple Sclerosis.” https://neurosciencenews.com/multiple-sclerosis-lymph-nodes-5077/ (accessed September 19, 2016).[/cbtab][/cbtabs]
Abstract
Reprogramming the Local Lymph Node Microenvironment Promotes Tolerance that Is Systemic and Antigen Specific
Highlights
•A single intra-lymph node (i.LN.) particle dose reverses autoimmunity/paralysis in mice
•Efficacy is dependent on delivery of encapsulated self-antigen to lymph nodes (LNs)
•i.LN. delivery of particles reprograms local LN cell composition and function
•Altered local function in LNs promotes systemic but antigen-specific tolerance
Summary
Many experimental therapies for autoimmune diseases, such as multiple sclerosis (MS), aim to bias T cells toward tolerogenic phenotypes without broad suppression. However, the link between local signal integration in lymph nodes (LNs) and the specificity of systemic tolerance is not well understood. We used intra-LN injection of polymer particles to study tolerance as a function of signals in the LN microenvironment. In a mouse MS model, intra-LN introduction of encapsulated myelin self-antigen and a regulatory signal (rapamycin) permanently reversed paralysis after one treatment during peak disease. Therapeutic effects were myelin specific, required antigen encapsulation, and were less potent without rapamycin. This efficacy was accompanied by local LN reorganization, reduced inflammation, systemic expansion of regulatory T cells, and reduced T cell infiltration to the CNS. Our findings suggest that local control over signaling in distinct LNs can promote cell types and functions that drive tolerance that is systemic but antigen specific.
“Reprogramming the Local Lymph Node Microenvironment Promotes Tolerance that Is Systemic and Antigen Specific” by Lisa H. Tostanoski, Yu-Chieh Chiu, Joshua M. Gammon, Thomas Simon, James I. Andorko, Jonathan S. Bromberg, and Christopher M. Jewell in Cell Reports. Published online August 10 2016 doi:10.1016/j.celrep.2016.08.033
